Cargando…

Safety and efficacy of topical, fixed‐dose combination calcipotriene (0.005%) and betamethasone (0.064% as dipropionate) gel in adolescent patients with scalp and body psoriasis: a phase II trial

BACKGROUND: Psoriasis is a disease that commonly manifests in adolescence. Up to half of adults with psoriasis develop it before the age of 20. Topical formulations containing corticosteroids and/or vitamin D3 analogs are recommended for treatment. OBJECTIVE: This phase II study aimed to evaluate th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Eichenfield, L.F., Marcoux, D., Kurvits, M., Liljedahl, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Pediatric Dermatology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318187/ https://www.ncbi.nlm.nih.gov/pubmed/31721327 http://dx.doi.org/10.1111/jdv.16077

Ejemplares similares

Safety and Efficacy of Calcipotriene Plus Betamethasone Dipropionate Topical Suspension in the Treatment of Extensive Scalp Psoriasis in Adolescents Ages 12 to 17 Years
por: Eichenfield, Lawrence F, et al.
Publicado: (2015)

Calcipotriene/betamethasone dipropionate for the treatment of psoriasis vulgaris: an evidence-based review
por: Patel, Nupur U, et al.
Publicado: (2017)

Short Term and Long-Term Efficacy of Calcipotriene/ Betamethasone Dipropionate Foam Combination
por: Jalili, Ahmad, et al.
Publicado: (2022)

In vivo quantitative MRI: T(1) and T(2) measurements of the human brain at 0.064 T
por: Jordanova, Kalina V., et al.
Publicado: (2023)

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy
por: Inoue, Kenji, et al.
Publicado: (2012)

Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam For Scalp Psoriasis
por: Anderko, Marian, et al.
Publicado: (2019)

Calcipotriene/betamethasone dipropionate foam: primary evidence supporting its use in patients with psoriasis vulgaris. A narrative review
por: Narbutt, Joanna, et al.
Publicado: (2021)

Safety and efficacy of calcipotriol plus betamethasone dipropionate gel in the treatment of scalp psoriasis in adolescents 12–17 years of age*
por: Gooderham, M, et al.
Publicado: (2014)

Retract p < 0.005 and propose using JASP, instead
por: Perezgonzalez, Jose D., et al.
Publicado: (2018)

Comparison of the latanoprost 0.005%/timolol 0.5% + brinzolamide 1% versus dorzolamide 1%/timolol 0.5% + latanoprost 0.005%: a 12-week, randomized open-label trial
por: Nakakura, Shunsuke, et al.
Publicado: (2012)

The assessment of intrinsic credibility and a new argument for p < 0.005
por: Held, Leonhard
Publicado: (2019)

Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris – A randomized phase II study
por: Koo, John, et al.
Publicado: (2016)

Supersaturation of Calcipotriene and Betamethasone Dipropionate in a Novel Aerosol Foam Formulation for Topical Treatment of Psoriasis Provides Enhanced Bioavailability of the Active Ingredients
por: Lind, Marianne, et al.
Publicado: (2016)

Adjunctive Use of Calcipotriene/Betamethasone Dipropionate Foam in a Real-World Setting Curtails the Cost of Biologics Without Reducing Efficacy in Psoriasis
por: Bagel, Jerry, et al.
Publicado: (2020)

Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline Characteristics
por: Lebwohl, Mark G., et al.
Publicado: (2021)

Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study
por: Molinelli, Elisa, et al.
Publicado: (2020)

Comparative study of the stability of bimatoprost 0.03% and latanoprost 0.005%: A patient-use study
por: Paolera, Mauricio D, et al.
Publicado: (2008)

An Applicator Delivery System for Fixed-Combination Calcipotriene Plus Betamethasone Dipropionate Topical Suspension (Gel): Innovating Psoriasis Vulgaris Treatment Through Patient Collaboration
por: Rasmussen, Gritt, et al.
Publicado: (2015)

Early Effect of 0.005% Estriol Vaginal Gel on Symptoms and Signs of Vulvovaginal Atrophy
por: Lázaro-Carrasco de la Fuente, Jesús, et al.
Publicado: (2022)

Plaque-Type Psoriasis Treated with Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam: A Prospective Study on Clinical and Dermoscopic Predictor Factors in Response Achievement and Retention
por: Errichetti, Enzo, et al.
Publicado: (2020)

En Coup de Sabre in a Pediatric Patient Treated With Calcipotriene
por: Coican, Alexis, et al.
Publicado: (2023)

Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris
por: Vakirlis, Efstratios, et al.
Publicado: (2008)

A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma
por: Mizoguchi, Takanori, et al.
Publicado: (2012)

Comparing the Efficacy of Latanoprost (0.005%), Bimatoprost (0.03%), Travoprost (0.004%), and Timolol (0.5%) in the Treatment of Primary Open Angle Glaucoma
por: Mishra, Deepak, et al.
Publicado: (2014)

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients
por: Miyashiro, Michael J, et al.
Publicado: (2010)

Once-daily topical treatment for psoriasis: calcipotriene + betamethasone two-compound topical formulation
por: Shepherd, Jonisha, et al.
Publicado: (2013)

Improved Efficacy of Topical Latanoprost 0.005% Demonstrated by Corneal Biomechanical Correcting Modified Goldmann Prism
por: Radcliffe, Nathan, et al.
Publicado: (2020)

Administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in glaucoma patients with an intraocular pressure over 30 mmHg
por: Özkurt, Yelda Buyru, et al.
Publicado: (2009)

Kinetics of Thermal Degradation of Betamethasone Valerate and Betamethasone Dipropionate in Different Media
por: Khattak, S. U. R., et al.
Publicado: (2012)

Calcipotriene and Betamethasone Dipropionate PAD-Cream Demonstrates Greater Treatment Efficacy in Patients with Moderate-to-Severe Psoriasis Compared to Topical Suspension/Gel: A Subgroup Analysis of Two Phase 3 Studies
por: Stein Gold, Linda, et al.
Publicado: (2023)

Efficacy and safety of switching to latanoprost 0.005%–timolol maleate 0.5% fixed-combination eyedrops from an unfixed combination for 36 months
por: Inoue, Kenji, et al.
Publicado: (2014)

The temperature stability of 0.005°C for the concrete floor in the CERN Transfer Tunnel #1 hosting the Precision Laser Inclinometer
por: Azaryan, N, et al.
Publicado: (2017)

Garnet-Based All-Ceramic Lithium Battery Enabled by Li(2.985)B(0.005)OCl Solder
por: Feng, Wuliang, et al.
Publicado: (2020)

Noninferiority Study Comparing Latanoprost 0.005% Without Versus With Benzalkonium Chloride in Open-Angle Glaucoma or Ocular Hypertension
por: Wirta, David, et al.
Publicado: (2022)

Trifarotene 0.005% Cream in the Treatment of Facial and Truncal Acne Vulgaris in Patients with Skin of Color: a Case Series
por: Del Rosso, James Q., et al.
Publicado: (2022)

A Randomized, Controlled Comparison of NCX 470 (0.021%, 0.042%, and 0.065%) and Latanoprost 0.005% in Patients With Open-angle Glaucoma or Ocular Hypertension: The Dolomites Study
por: Walters, Thomas R., et al.
Publicado: (2022)

A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension
por: Godfrey, David A, et al.
Publicado: (2009)

Crossover randomized study comparing the efficacy and tolerability of preservative-free Tafluprost 0.0015% to Latanoprost 0.005% in patients with primary open-angle glaucoma
por: Hagras, Sherein M, et al.
Publicado: (2021)

Nanocarrier-based hydrogel of betamethasone dipropionate and salicylic acid for treatment of psoriasis
por: Baboota, Sanjula, et al.
Publicado: (2011)

Calcipotriol/Betamethasone Dipropionate Cutaneous Foam Treatment for Psoriasis in Patients With BSA 5–15% and PGA ≥ 3: Post-Hoc Analysis From Three Randomized Controlled Trials
por: Iversen, Lars, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_muafrji47n07eqkqd6qsujoops